Tipo |
Título / Nombre |
Autor(es) |
Año |
|
Post-Remission Treatment with Chemotherapy or Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) in Adult Patients with High-Risk (HR) Philadelphia Chromosome-Negative (Ph-neg) Acute Lymphoblastic Leukemia (ALL) According to Their Minimal Residual Disease (MRD). Final Results of the Pethema ALL-HR-11 Trial |
Ribera JM, Morgades M, Prob M, Ciudad J, Montesinos P, Barba P, García-Cadenas I, Moreno MJ, Vives S, Esteve J, Gil C, Monsalvo S, Artola MT, Ribera J, Genesca E, Tormo M, Cervera M, Martínez Carballeira D, Novo A, González Campos J, Soria B, Bermúdez A, López Martínez A, Mercadal S, Fernández Martín R, Coll R, Serrano J, Amigo ML, Martínez Sánchez P, Bergua JM, Serrano Maestro A, Giménez Conca A, Barrera S, Granada I, Feliu E, Orfao A |
2019 |
|
Update on management and progress of novel therapeutics for R/R AML: an Iberian expert panel consensus |
Montesinos P, Bergua J, Infante J, Esteve J, Guimaraes JE, Sierra J, Sanz MÁ |
2019 |
|
Clinicobiologic characteristics and outcome of elderly frail patients with acute lymphoblastic leukemia included in a specific protocol (all-07FRAIL) |
Ribera JM, García Calduch O, Gil C, González Campos J, Moreno MJ, Barba P, Amigo ML, Martinez Carballeira D, Alonso N, Bergua JM, Mercadal S, Cladera A, Vall Llovera F, García Guinon A, López A, Lavilla E, Sierra M, Hernández Rivas JM |
2019 |
|
Differences in ex-vivo Chemosensitivity to Anthracyclines in First Line Acute Myeloid Leukemia |
Megías-Vericat JE, Martínez-Cuadrón D, López JM, Bergua JM, Tormo M, Serrano J, González AA, de Oteyza JP, Vives S, Vidriales B, Herrera P, Vera JA, Martínez AL, de la Fuente A, Amador ML, Hernández-Rivas JÁ, Fernández MÁ, Cerveró CJ, Morillo D, Campo PH, Gorrochategui J, Primo D, Rojas JL, Guenova M, Ballesteros J, Sanz M, Montesinos P |
2019 |
|
DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy |
Sánchez-Correa B, Valhondo I, Hassouneh F, López-Sejas N, Pera A, Bergua JM, Arcos MJ, Bañas H, Casas-Avilés I, Durán E, Alonso C, Solana R, Tarazona R |
2019 |
|
Coexistence of ymphoplasmacytic lymphoma, multiple myeloma and myelodysplastic syndrome |
Cáceres Hernández S, Bañas Llanos H, Arcos Carmona MJ, Cardesa Cabrera R, Suárez Varela S, Casas Avilés I, Moriano Palacios B, Espina García M, Rodríguez López A, Ibañez Espacio F, Bermejo Vega N, Cabrera C, Carnicero González F, Bergua Burgués J |
2019 |
|
LMA NPM1 tras TE JAK2V617F: ¿transformación leucémica u origen de novo? |
Moriano Palacios BJ, Ferre Bermejo O, Cardesa Cabrera R, Suárez-Varela Pineda S, Cáceres Hernández S, Rodríguez López A, Espina García M, Bañas Llanos H, Arcos Carmona MJ, Ibáñez Espacio F, Bermejo Vega N, Cabrera Silva C, Prieto Fernández J, Carnicero González F, Bergua Burgués JM |
2019 |
|
Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy |
Labrador J, Luño E, Vellenga E, Brunet S, González-Campos J, Chillón MC, Holowiecka A, Esteve J, Bergua J, González-Sanmiguel JD, Gil C, Tormo M, Salamero O, Manso F, Fernández I, de laSerna J, Moreno MJ, Pérez-Encinas M, Krsnik I, Ribera JM, Cervera J, Calasanz MJ, Boluda B, Sobas M, Lowenberg B, Sanz MA, Montesinos P |
2019 |
|
A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients |
Martínez-Cuadrón D, Gil C, Serrano J, Rodríguez G4, Pérez-Oteyza J, García-Boyero R, Jiménez-Bravo S, Vives S, Vidriales MB, Lavilla E, Pérez-Simón JA, Tormo M, Colorado M, Bergua J, López JA, Herrera P, Hernández Campos P, Gorrochategui J, Primo D, Rojas JL, Villoria J, Moscardó F, Troconiz I, Linares Gómez M, Martínez-López J, Ballesteros J, Sanz M, Montesinos P, Spanish PETHEMA group |
2019 |
|
An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens |
Sobas M, Montesinos P, Boluda B, Bernal T, Vellenga E, Nomdedeu J, González-Campos J, Chillón M, Holowiecka A, Esteve J, Bergua J, González-Sanmiguel JD, Gil-Cortes C, Tormo M, Salamero O, Manso F, Fernández I, de la Serna J, Moreno MJ, Pérez-Encinas M, Krsnik I, Ribera JM, Escoda L, Lowenberg B, Sanz MA, PETHEMA, HOVON, PALG, and GATLA cooperative groups |
2019 |